Granulocyte colony-stimulating factor (G-CSF ), granulocyte-microphage colony-stimulating factor (GM- CSF ) is specific hematopoietic regulating growth factor of granulocyte lineage, granulocyte-monocyte lineage, resp...Granulocyte colony-stimulating factor (G-CSF ), granulocyte-microphage colony-stimulating factor (GM- CSF ) is specific hematopoietic regulating growth factor of granulocyte lineage, granulocyte-monocyte lineage, respectively. G-CSF. GM-CSF can promote the proliferation, differentiation and mature of its hematopoietic progenitor and enhance the function of mature blood cell. Their gene recombinant human products have been widely applied to clinical practice. The effects of G-GSF. GM-CSF in clinical application are as follows (l ) reducing malignant tumor chemotherapy-related neutropenia, duration of neutropenia, infections and resulting treatment delays. (2 ) mobilizing peripheral blood stem progenitor cell and speeding hematopoietic reconstituation following allogeneic and autologous stem progenitor transplantation. The recent clinical application of G-CSF. GM-CSF has been summarized in this review.展开更多
目的探讨Krüppel样转录因子9(KLF9)在上皮性卵巢癌中的表达及其临床意义。方法选取63例有完整临床病理资料及随访>5年的石蜡包埋上皮性卵巢癌组织和正常卵巢上皮组织。采用实时荧光定量聚合酶链反应检测KLF9 m RNA在两组卵巢组...目的探讨Krüppel样转录因子9(KLF9)在上皮性卵巢癌中的表达及其临床意义。方法选取63例有完整临床病理资料及随访>5年的石蜡包埋上皮性卵巢癌组织和正常卵巢上皮组织。采用实时荧光定量聚合酶链反应检测KLF9 m RNA在两组卵巢组织中的表达,应用免疫组织化学法分析KLF9在两组卵巢中的表达,分析KLF9表达水平与临床病理参数及患者预后的关系。结果 63例卵巢癌组织中,KLF9 m RN为正常上皮组织的(0.44±0.693)倍(P<0.05)。上皮性卵巢癌组织中,KLF9高表达15例(23.8%),低表达48例(76.2%);在正常卵巢组织中,KLF9高表达18例(60%),低表达12例(40%),差异有统计学意义(P<0.05)。癌组织中KLF9低表达与上皮性卵巢癌患者的临床分期、淋巴结转、腹腔积液相关(P<0.05)。KLF9 m RNA高表达组中位生存时间46.8个月(95%CI:26,83),高于低表达组的32.6个月[(95%CI:12,74),P=0.002]。肿瘤组织中KLF9阳性细胞高表达组的中位生存时间为50.2个月(95%CI:32,84),高于KLF9低表达组的31.1个月[(95%CI:12,79),P=0.001]。多因素COX生存分析表明,KLF9 m RNA和KLF9阳性细胞低表达是影响上皮性卵巢癌预后不良的独立指标[HR=2.64(95%CI:1.14,3.56),P=0.017]和[HR=3.01(95%CI:2.19,4.51),P=0.010]。结论KLF9在上皮性卵巢癌组织中表达下调,与上皮性卵巢癌患者预后不良相关。展开更多
文摘Granulocyte colony-stimulating factor (G-CSF ), granulocyte-microphage colony-stimulating factor (GM- CSF ) is specific hematopoietic regulating growth factor of granulocyte lineage, granulocyte-monocyte lineage, respectively. G-CSF. GM-CSF can promote the proliferation, differentiation and mature of its hematopoietic progenitor and enhance the function of mature blood cell. Their gene recombinant human products have been widely applied to clinical practice. The effects of G-GSF. GM-CSF in clinical application are as follows (l ) reducing malignant tumor chemotherapy-related neutropenia, duration of neutropenia, infections and resulting treatment delays. (2 ) mobilizing peripheral blood stem progenitor cell and speeding hematopoietic reconstituation following allogeneic and autologous stem progenitor transplantation. The recent clinical application of G-CSF. GM-CSF has been summarized in this review.
文摘目的探讨Krüppel样转录因子9(KLF9)在上皮性卵巢癌中的表达及其临床意义。方法选取63例有完整临床病理资料及随访>5年的石蜡包埋上皮性卵巢癌组织和正常卵巢上皮组织。采用实时荧光定量聚合酶链反应检测KLF9 m RNA在两组卵巢组织中的表达,应用免疫组织化学法分析KLF9在两组卵巢中的表达,分析KLF9表达水平与临床病理参数及患者预后的关系。结果 63例卵巢癌组织中,KLF9 m RN为正常上皮组织的(0.44±0.693)倍(P<0.05)。上皮性卵巢癌组织中,KLF9高表达15例(23.8%),低表达48例(76.2%);在正常卵巢组织中,KLF9高表达18例(60%),低表达12例(40%),差异有统计学意义(P<0.05)。癌组织中KLF9低表达与上皮性卵巢癌患者的临床分期、淋巴结转、腹腔积液相关(P<0.05)。KLF9 m RNA高表达组中位生存时间46.8个月(95%CI:26,83),高于低表达组的32.6个月[(95%CI:12,74),P=0.002]。肿瘤组织中KLF9阳性细胞高表达组的中位生存时间为50.2个月(95%CI:32,84),高于KLF9低表达组的31.1个月[(95%CI:12,79),P=0.001]。多因素COX生存分析表明,KLF9 m RNA和KLF9阳性细胞低表达是影响上皮性卵巢癌预后不良的独立指标[HR=2.64(95%CI:1.14,3.56),P=0.017]和[HR=3.01(95%CI:2.19,4.51),P=0.010]。结论KLF9在上皮性卵巢癌组织中表达下调,与上皮性卵巢癌患者预后不良相关。
